• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Nod for Bracco’s Barium-Sulfate Oral Suspension


FDA approves Bracco’s READI-CAT 2 and READI-CAT 2 SMOOTHIE for use in abdominal CT.

The U.S. Food and Drug Administration has approved a New Drug Application for READI-CAT 2 and READI-CAT 2 SMOOTHIE, barium sulfate oral suspensions for use in CT.

READI-CAT 2 and READI-CAT 2 SMOOTHIE, products of Bracco Imaging, a subsidiary of Bracco Diagnostics, are used in CT of the abdomen to delineate the gastrointestinal tract in adult and pediatric patients, a release said.

This approval is the second regulatory approval of a barium-based contrast agent in the U.S., and the first for use in modern CT imaging, Bracco’s release said.

READI-CAT 2 is supplied in 450 mL bottles; READI-CAT 2 SMOOTHIES, also in 450 mL bottles, are available for use by adult and pediatric patients in berry, banana, creamy vanilla and mochaccino flavors.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.